Plain-English translation of NCT04941716 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether combining two medications — and — can help people whose blood cancer (chronic lymphocytic leukemia or small lymphocytic lymphoma) has returned or stopped responding to prior treatments. You would take twice daily for the first three months, then add once daily to the regimen. The goal is to see if this combination can shrink the cancer and help you live longer.
Many patients with this type of blood cancer eventually stop responding to their initial treatment, leaving them with limited options. This trial is exploring whether this medication combination can be more effective for people in that situation.
You likely qualify if…
You likely don't qualify if…
You would take the medications by mouth every day for up to 26 months (about 2 years), with treatment organized into monthly cycles. Throughout the trial, you would have regular clinic visits for blood tests, occasional bone marrow biopsies, and imaging scans to monitor how the cancer responds. After finishing treatment, you would continue with follow-up visits every three months for the first year, then annually for ten years to track your long-term health.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
United States